Clinical Trial

Finding Links Between Hot flASHes and CardioVascular Disease

Study acronym: FLASH-CV:
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn if neurokinin-1/neurokinin-3 receptor antagonist elinzanetant improves blood vessel health in women with moderate to severe hot flashes. The main questions it aims to answer is does neurokinin-1/neurokinin-3 receptor antagonist elinzanetant improve blood vessel health?
Protocol Amendment History 3 changes
critical Recruitment opened 2026-05-21
notable Primary completion moved earlier: 2029-10 -> 2029-06 2026-05-21
minor Completion moved earlier: 2030-10 -> 2029-09 2026-05-21
Trial Details
NCT Number NCT07077395
Lead Sponsor Massachusetts General Hospital
Conditions Menopause-related Hot Flashes
Enrollment 80 participants
Start Date 2026-03-01
Primary Completion 2029-06 (estimated)
Study Completion 2029-09 (estimated)
Updated on ClinicalTrials.gov 2026-05-20